Advances in nucleoside monophosphate prodrugs as anti-HCV agents

被引：51

作者：

Bobeck, Drew R. ^{[1
]}

Schinazi, Raymond F. ^{[2
,3
]}

Coats, Steven J. ^{[1
]}

机构：

[1] RFS Pharma LLC, Tucker, GA USA

[2] Emory Univ, Sch Med, Dept Pediat, Biochem Pharmacol Lab,Ctr AIDS Res, Decatur, GA 30033 USA

[3] Vet Affairs Med Ctr, Decatur, GA 30033 USA

来源：

ANTIVIRAL THERAPY | 2010年 / 15卷 / 07期

关键词：

HEPATITIS-C VIRUS; PHOSPHORAMIDATE PROTIDE APPROACH; HEPDIRECT PRODRUGS; RNA REPLICATION; INACTIVE NUCLEOSIDE; POTENT INHIBITORS; NS5B POLYMERASE; IN-VITRO; INFECTION; THERAPY;

D O I：

10.3851/IMP1667

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

Nucleoside monophosphate prodrugs that are eventually bioconverted to the active nucleoside triphosphate (NTP) offer the potential to deliver increased intracellular NTP levels and/or organ-specific NIP enhancement. There are several classes of monophosphate prodrugs that have been applied to HCV drug discovery, and some of these approaches are currently being evaluated in humans. This review discusses recent advances in monophosphate prodrug approaches to improve oral absorption, stability and pharmacokinetic profile, including their advantages and potential pitfalls.

引用

页码：935 / 950

页数：16

共 75 条

[1]

ARENDS JE, 2009, 49 INT C ANT AG CHEM

[2]

Benzaria Samira, 2007, Antiviral Chemistry & Chemotherapy, V18, P225

[3]

BOOKSER BC, 2009, Patent No. 069095

[4]

High-throughput synthesis of HepDirect prodrugs of nucleoside monophosphates [J].